愿景：JAMA Oncology致力于發(fā)表有影響力的原創(chuàng)研究、意見和評(píng)論，促進(jìn)腫瘤學(xué)和改善癌癥患者的臨床護(hù)理。使命：JAMA腫瘤學(xué)是全球腫瘤學(xué)領(lǐng)域的科學(xué)家、臨床醫(yī)生和培訓(xùn)生的權(quán)威期刊。我們?cè)瓌?chuàng)的、創(chuàng)新的、及時(shí)的科學(xué)和教育內(nèi)容為讀者提供了對(duì)癌癥發(fā)病機(jī)制和最新治療進(jìn)展的更深入的了解。JAMA腫瘤學(xué)旨在有效地將重要臨床研究成果、重大科學(xué)突破、可操作的發(fā)現(xiàn)和最先進(jìn)的治療方法傳達(dá)給腫瘤學(xué)社區(qū)。我們的目標(biāo)是，新知識(shí)的成功交流最終將轉(zhuǎn)化為癌癥患者和幸存者的臨床利益。編輯團(tuán)隊(duì)。《美國(guó)醫(yī)學(xué)會(huì)腫瘤雜志》的創(chuàng)始主編是瑪麗·l·迪斯(Nora)，醫(yī)學(xué)博士。迪斯博士是華盛頓大學(xué)(UW)的醫(yī)學(xué)教授、病理學(xué)和婦產(chǎn)科副教授，弗雷德·哈欽森癌癥研究中心的成員。她是華盛頓大學(xué)醫(yī)學(xué)院轉(zhuǎn)化科學(xué)副院長(zhǎng)，華盛頓大學(xué)轉(zhuǎn)化醫(yī)學(xué)和婦女健康中心主任，以及華盛頓大學(xué)轉(zhuǎn)化健康科學(xué)研究所主任。迪斯博士是乳腺癌和卵巢癌、免疫治療和轉(zhuǎn)化研究方面的專家。有關(guān)《華爾街日?qǐng)?bào)》編輯和編輯委員會(huì)的完整列表，請(qǐng)參見下面的編輯和出版商鏈接。期刊出版及編輯資訊。JAMA Oncology是一份經(jīng)同行評(píng)審的國(guó)際期刊，每周四在網(wǎng)上出版，每月出版一期。錄取率為21%。初始編輯決定的時(shí)間為1天不審核，35天有審核。所有的文章都是先在網(wǎng)上發(fā)表的，平均接受時(shí)間為71天。所有研究論文出版后12個(gè)月免費(fèi)在線閱讀。所有文章在出版當(dāng)天都可以免費(fèi)訪問JAMA網(wǎng)絡(luò)閱讀器。JAMA Oncology也為合格手稿的作者提供了開放存取的選擇。有關(guān)詳細(xì)信息，請(qǐng)參閱作者說明。此外，通過世界衛(wèi)生組織的HINARI項(xiàng)目，該雜志向發(fā)展中國(guó)家的機(jī)構(gòu)免費(fèi)提供或幾乎免費(fèi)提供。感興趣的話題。《美國(guó)醫(yī)學(xué)會(huì)腫瘤學(xué)》發(fā)表關(guān)于醫(yī)學(xué)、放射、外科腫瘤學(xué)及其分支學(xué)科的所有方面的論文，包括以下主題:乳腺癌癌癥生物標(biāo)記物癌癥遺傳學(xué)癌癥相關(guān)的并發(fā)癥癌癥治療骨髓/干細(xì)胞移植化療新的治療方法治療相關(guān)的并發(fā)癥臨床指南臨床試驗(yàn)診斷和分期藥物發(fā)現(xiàn)內(nèi)分泌系統(tǒng)癌癥流行病學(xué)，癌癥預(yù)防和控制胃腸道癌癥膽道癌結(jié)腸癌食道癌胃癌肝癌癥胰腺癌直腸癌泌尿生殖器的癌癥前列腺癌腎癌泌尿道腫瘤老年腫瘤學(xué)婦科癌癥子宮頸癌子宮內(nèi)膜癌卵巢癌頭頸癌血液惡性腫瘤成像免疫療法肺癌Neuro-oncology腦癌中樞神經(jīng)系統(tǒng)癌姑息治療癌癥的支持性護(hù)理疼痛控制兒科癌癥質(zhì)量和衛(wèi)生服務(wù)研究經(jīng)濟(jì)學(xué)衛(wèi)生政策放射腫瘤學(xué)肉瘤皮膚癌黑素瘤軟組織腫瘤平移腫瘤學(xué)未知的原發(fā)部位和罕見的癌癥JAMA腫瘤學(xué)ISSN 2374 - 2437(印刷)ISSN 2374 - 2445(在線)2016年4月更新

Vision. JAMA Oncology is committed to publishing influential original research, opinions, and reviews that advance the science of oncology and improve the clinical care of patients with cancer.Mission. JAMA Oncology is the definitive journal for scientists, clinicians, and trainees in the field of oncology worldwide. Our original, innovative, and timely scientific and educational content provides a deeper understanding of cancer pathogenesis and recent treatment advances for our readers.JAMA Oncology aims to effectively convey the findings of important clinical research, major scientific breakthroughs, actionable discoveries, and state-of-the-art treatment pathways to the oncology community. Our goal is that successful communication of new knowledge will ultimately translate to clinical benefit for people living with and surviving cancer.Editorial Team. The founding Editor in Chief of JAMA Oncology is Mary L. (Nora) Disis, MD. Dr Disis is a Professor of Medicine and Adjunct Professor of Pathology and Obstetrics and Gynecology at the University of Washington (UW), and a Member of the Fred Hutchinson Cancer Research Center. She is the Associate Dean for Translational Science in the UW School of Medicine, Director of the UW Center for Translational Medicine and Women''''''''s Health, and Director, UW Institute for Translational Health Sciences. Dr Disis is an expert in breast and ovarian cancer, immunotherapy, and translational research. For a complete listing of the journal’s Editors and Editorial Board, see link to Editors and Publishers below.Journal Publication and Editorial Information. JAMA Oncology is an international peer-reviewed journal that is published online each Thursday and in a print/online issue every month. The acceptance rate is 21%. Time to initial editorial decision is 1 day without review and 35 days with review. All articles are published Online First within a median of 71 days of acceptance. All research articles are made free access online 12 months after publication. All articles are made free access on The JAMA Network Reader on the day of publication. JAMA Oncology also has an open access option for authors of eligible manuscripts. See Instructions for Authors for details. In addition, the journal is made freely available or nearly so to institutions in developing countries through the World Health Organization''''''''s HINARI program.Topics of Interest. JAMA Oncology publishes papers on all aspects medical, radiation, and surgical oncology and its subspecialties, including the following Topics: Breast Cancer Cancer Biomarkers Cancer Genetics Cancer-Related Complications Cancer Therapy and Treatment Bone Marrow/Stem Cell Transplantation Chemotherapy Novel Therapies Treatment-Related Complications Clinical Guidelines Clinical Trials Diagnosis and Staging Drug Discovery Endocrine System Cancer Epidemiology, Cancer Prevention, and Control Gastrointestinal Cancer Biliary Cancer Colon Cancer Esophageal Cancer Gastric Cancer Hepatic Cancer Pancreatic Cancer Rectal Cancer Genitourinary Cancer Prostate Cancer Renal Cancer Urinary Tract Cancer Geriatric OncologyGynecologic CancerCervical CancerEndometrial CancerOvarian CancerHead & Neck CancerHematologic MalignanciesImagingImmunotherapyLung CancerNeuro-oncologyBrain CancerCentral Nervous System CancerPalliative CareCancer Supportive CarePain ControlPediatric CancerQuality and Health Services ResearchEconomicsHealth PolicyRadiation OncologySarcomasSkin CancerMelanomaSoft-Tissue TumorsTranslational OncologyUnknown Primary Site and Rare CancersJAMA OncologyISSN 2374-2437 (Print)ISSN 2374-2445 (Online)Updated April 2016